TGFB1 and pulmonary fibrosis: Although some experimental and preclinical studies have suggested a potential protective effect of losartan against lung fibrosis and inflammation through TGF-β modulation and attenuation of AngII activity (48) these findings have not been supported by robust clinical evidence.